Basic Search
|
Summaries
|
Advanced SearchViolation Tracker Individual Record
Company: Watson Laboratories
Current Parent Company:
Teva Pharmaceutical Industries
Parent at the Time of the Penalty Announcement:
subscribe to see this data field
Recap of Ownership Changes:
subscribe to see this data field
Penalty: $50,000,000
Year: 2016
Date: August 15, 2016
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal:
Generic Drug Pay for Delay
Violation Description: Hoechst Marion Roussel and Watson Laboratories together agreed to pay $100 million to settle their role in litigation concerning an arrangement to delay the introduction of a generic version of the antibiotic Cipro. Court documents did not indicate how much each would pay. Here we assume they each paid half of the total.
Level of Government: state
Action Type: private litigation
Court: San Diego County (CA) Superior Court
Civil or Criminal Case: civil
Case ID: Judicial Council Coordination Proceeding Nos. 4154 and 4220
Case Name: CIPRO CASES I and II
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: Israel
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data:
(click here)
Link to Archived Court Document:
subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker
Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the
Update Log.